5 results
Articles
A New Guide for Promotional Labeling and Advertising of Biosimilar Products A New Guide for Promotional Labeling and Advertising of Biosimilar Products
May 26, 2020
Biosimilar DevelopmentIP Health Blog
FDA Draft Guidance on Biosimilar and Interchangeable Insulin Products FDA Draft Guidance on Biosimilar and Interchangeable Insulin Products
December 27, 2019
IP Health Blog
FDA Final Guidance on Application of Statutory Factors in Determining When a REMS is Necessary FDA Final Guidance on Application of Statutory Factors in Determining When a REMS is Necessary
April 11, 2019
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.